Active Ingredient History
Nitroprusside is a medication which is used to lower blood pressure. It is comprised of a ferrous ion complexed with five cyanide and one nitrosyl group. Upon intravenous infusion, nitroprusside interacts with oxyhemoglobin and dissociates, releasing cyanide and nitric oxide, which act as a powerful vasodilating agent. Sodium nitroprusside was approved by the FDA in 1974 and is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Sodium Nitroprusside injection is also indicated for producing controlled hypotension in order to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. NCATS
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Heart Failure (approved 1974)
Hypertension (approved 1974)
Acute Lung Injury (Phase 1)
Aging (Phase 1)
Anemia (Phase 2)
Anesthesia and Analgesia (Early Phase 1)
Autonomic Nervous System Diseases (Phase 1)
Breast Neoplasms (Phase 1/Phase 2)
Cardiovascular Diseases (Phase 1)
Depression (Phase 2)
Dopamine beta-Hydroxylase (Phase 1)
Extracorporeal Membrane Oxygenation (Phase 2)
Healthy Volunteers (Phase 4)
Heart Disease Risk Factors (Phase 1)
Heart Failure (Phase 4)
Hemorrhagic Stroke (Phase 4)
Hyperlipidemias (Phase 2)
Hypertension (Phase 3)
Hypertension, Pulmonary (Phase 1)
Hypotension (Phase 2)
Hypotension, Orthostatic (Phase 1)
Hypoxia (Phase 1)
Inflammation (Phase 1)
Leukemia (Phase 1/Phase 2)
Lymphoma (Phase 1/Phase 2)
Myocardial Infarction (Phase 4)
Nitroprusside (Phase 4)
Obesity (Early Phase 1)
Orthostatic Intolerance (Phase 1)
Psychotic Disorders (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 1)
Respiratory Distress Syndrome (Phase 1)
Respiratory Insufficiency (Phase 1)
Sarcopenia (Phase 1)
Schizophrenia (Phase 2)
Stress Disorders, Post-Traumatic (Phase 2)
Thyroid Hormones (Phase 4)
Vascular Stiffness (Early Phase 1)
Vasoconstriction (Phase 1)
Vasodilation (Early Phase 1)
Vasodilator Agents (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue